drugset
drugset / Trial / NCT04746209

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

NCT04746209 ↗

Phase 2 Recruiting 25 enrolled Medical College of Wisconsin Amgen · collabUniversity of Wisconsin, Madison · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.

Timeline

Start
2021-02-01
Primary completion
2024-02-28
Completion
2029-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Blinatumomab Monoclonal antibody — —

Indications

B-cell acute lymphoblastic leukemia B-cell childhood acute lymphoblastic leukemia